中文名 | EHop-016 |
英文名 | EHop-016 |
别名 | EHOP-016游离态 RAC GTPASE抑制剂(EHOP-016) N4-(9-乙基-9H-咔唑-3-基)-N2-[3-(4-吗啉基)丙基]-2,4-嘧啶二胺 |
英文别名 | EHOP016 EHOP 016 EHop-016 EHOP016 EHOP-016 EHOP-016 EHOP 016 EHOP 016. N4-(9-Ethyl-9H-carbazol-3-yl)-N2-[3-(4-morpholinyl)propyl]-2,4-pyrimidinediamine N4-(9-ETHYL-9H-CARBAZOL-3-YL)-N2-(3-MORPHOLIN-4-YL-PROPYL)-PYRIMIDINE-2,4-DIAMINE N4-(9-Ethyl-9H-carbazol-3-yl)-N2-(3-Morpholin-4-yl-propyl)-pyriMidine-2,4-diaMine EHOP-016 N4-(9-ETHYL-9H-CARBAZOL-3-YL)-N2-(3-MORPHOLIN-4-YL-PROPYL)-PYRIMIDINE-2,4-DIAMINE N4-(9-Ethyl-9H-carbazol-3-yl)-N2-[3-(4-morpholinyl)propyl]-2,4-pyrimidinediamine Ehop-016 |
CAS | 1380432-32-5 |
化学式 | C25H30N6O |
分子量 | 430.55 |
密度 | 1.27 |
沸点 | 633.9±65.0 °C(Predicted) |
溶解度 | DMSO: 溶解10mg/mL,澄清 |
酸度系数 | 7.30±0.10(Predicted) |
存储条件 | 2-8°C |
外观 | 粉末 |
颜色 | white to beige |
MDL号 | MFCD23143628 |
体外研究 | EHop-016 (1-10 μM; 24 hours; MDA-MB-435 cells) treatment inhibits Rac1 and Rac3 activity. At higher concentrations, EHop-016 inhibits the close homolog Cdc42. In MDA-MB-435 cells that demonstrate high active levels of the Rac GEF Vav2, EHop-016 inhibits the association of Vav2 with a nucleotide-free Rac1(G15A) . EHop-016 also inhibits the Rac activity of MDA-MB-231 metastatic breast cancer cells and reduces Rac-directed lamellipodia formation in both cell lines. EHop-016 decreases Rac downstream effects of PAK1 (p21-activated kinase 1) activity and directed migration of metastatic cancer cells. EHop-016 affectes cell viability by down-regulating Akt and Jun kinase activities and c-Myc and Cyclin D expression, as well as increasing caspase 3/7 activities in metastatic cancer cells. Western Blot Analysis Cell Line: MDA-MB-435 cells Concentration: 1 μM, 2 μM, 4 μM, 5 μM, 10 μM Incubation Time: 24 hours Result: The activity Rac3 was inhibited by 58%. |
体内研究 | EHop-016 (10-25 mg/kg; intraperitoneal injection; 3 times a week; for 55 days; nu/nu mice) treatment significantly reduces mammary fat pad tumor growth, metastasis, and angiogenesis. Animal Model: Female athymic nu/nu mice (4-5 weeks old) injected with GFP-MDA-MB-435 cells Dosage: 10 mg/kg, 25 mg/kg Administration: Intraperitoneal injection; 3 times a week; for 55 days Result: Significantly reduced mammary fat pad tumor growth, metastasis, and angiogenesis. |
WGK Germany | 3 |
上游原料 | N-(3-氨丙基)吗啉 3-氨基-9-乙基咔唑 |
参考资料 展开查看 | 1: Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, Tiu RV, Vlaar CP, Dharmawardhane S, Kapur R. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest. 2013 Oct 1;123(10):4449-63. doi: 10.1172/JCI67509. Epub 2013 Sep 16. PubMed PMID: 24091327; PubMed Central PMCID: PMC3784531. 2: Dharmawardhane S, Hernandez E, Vlaar C. Development of EHop-01 6: a small molecule inhibitor of Rac. Enzymes. 2013;33 Pt A:117-46. doi: 10.1016/B978-0-12-416749-0.00006-3. Epub 2013 Aug 8. Review. PubMed PMID: 25033803. 3: Montalvo-Ortiz BL, Castillo-Pichardo L, Hernández E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA, Vlaar CP, Dharmawardhane S. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase. J Biol Chem. 2012 Apr 13;287(16):13228-38. doi: 10.1074/jbc.M111.334524. Epub 2012 Mar 1. PubMed PMID: 22383527; PubMed Central PMCID: PMC3339933. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.323 ml | 11.613 ml | 23.226 ml |
5 mM | 0.465 ml | 2.323 ml | 4.645 ml |
10 mM | 0.232 ml | 1.161 ml | 2.323 ml |
5 mM | 0.046 ml | 0.232 ml | 0.465 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!